Compare JJSF & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | CRVS |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | United States |
| Employees | 1800 | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 1995 | 2016 |
| Metric | JJSF | CRVS |
|---|---|---|
| Price | $78.58 | $9.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $110.50 | $33.14 |
| AVG Volume (30 Days) | 193.6K | ★ 1.2M |
| Earning Date | 11-16-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $1,022,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $39.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $68.87 | $6.39 |
| 52 Week High | $98.63 | $26.95 |
| Indicator | JJSF | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 30.01 |
| Support Level | $72.93 | $6.39 |
| Resistance Level | $78.56 | $13.73 |
| Average True Range (ATR) | 2.03 | 0.59 |
| MACD | 0.23 | -0.06 |
| Stochastic Oscillator | 29.34 | 11.37 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.